ADIL

Adial Pharmaceuticals
ADIL
Market cap $6.85M

1.07 USD

+0.02

1.90%

At close Dec 20, 4:00 PM EST

After hours

1.05

-0.02

1.87%

1 day

1.90%

5 days

-2.73%

1 month

4.90%

3 months

1.90%

6 months

-2.73%

Year to date

-38.86%

1 year

-38.15%

5 years

-98.15%

10 years

-98.94%

About: Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Employees: 7

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

3.68% less ownership

Funds ownership: 6.71% [Q2] → 3.03% (-3.68%) [Q3]

27% less funds holding

Funds holding: 15 [Q2] → 11 (-4) [Q3]

40% less capital invested

Capital invested by funds: $326K [Q2] → $194K (-$132K) [Q3]

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$8

648%

upside

Avg. target

$8

648%

upside

High target

$8

648%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Rodman & Renshaw

Brandon Folkes

54% 1-year accuracy

7 / 13 met price target

648%upside

$8

Buy

Initiated

14 Nov 2024

See Analyst Rankings

Financial journalist opinion

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, expanding the Company's intellectual property coverage.

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Zacks Investment Research

Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024.

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Glen Allen, VA, October 23, 2024 – PRISM MediaWire – Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York.

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced database lock for the pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2024.

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during the fourth quarter GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the final patient has completed the last dose in the pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Expected New Patent Based on Extensive Review of Data and Information Expected New Patent Based on Extensive Review of Data and Information

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

See News Rankings

Charts implemented using Lightweight Charts™